Le Lézard
Classified in: Health, Science and technology
Subject: TRADE SHOWS/SEMINARS/WEBINARS

Aquinox to Present at Deutsche Bank 43rd Annual Healthcare Conference


VANCOUVER, British Columbia, May 02, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, announced today that David Main, President & CEO, will provide a corporate update at the upcoming Deutsche Bank 43rd Annual Healthcare Conference in Boston on Wednesday, May 9th 2018.

Aquinox Presentation Details

Date: Wednesday, May 9th 2018
Time: 6:20 am Pacific Time / 9:20 am Eastern Time                                  
Location: Boston, MA ? Intercontinental Hotel Boston

A live webcast and archive of the event will be available at:

https://edge.media-server.com/m6/p/oiye7bcp

To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.

About Aquinox Pharmaceuticals, Inc.

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox's lead drug candidate, rosiptor (AQX-1125), is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a condition for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit www.aqxpharma.com.

Investor Contact Info:

Brendan Payne
Associate Director, Investor Relations 
Aquinox Pharmaceuticals, Inc.
604.901.3019
[email protected]

Gitanjali Ogawa
Vice President 
The Trout Group?
646-378-2949?
[email protected]


These press releases may also interest you

at 23:19
Summit Clinical Research Statement on Co-Founder and Chairman Dr. Stephen Harrison
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

at 22:15
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

at 21:59
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 21:27
Labcorp Announces Winning Bid for Select Assets of Invitae
Labcorp , a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed,...

at 21:19
Invitae Enters into Agreement with Labcorp for Sale of Business
Invitae , a leading medical genetics company, announced that Labcorp , a global leader of innovative and comprehensive laboratory services, has been selected...

at 21:05
/C O R R E C T I O N -- Valcare Medical/
Valcare Medical, Inc., a leading innovator in transcatheter-based mitral...

More news about Health...


News published on and distributed by: